论文部分内容阅读
我院自1989年以来开展血卟啉加术前放疗治疗食管癌,取得临床观察资料。本文重点观察血卟啉加放疗对食管切除标本的病理学变化。材料与方法:10例食管癌病人均经胃镜活检病理诊断为鳞状上皮癌,并经外科检查认为手术有困难者(①病变较长,在6厘米以上,伴有外侵;②病变紧靠主动脉、气管、心脏等重要器官,估计粘连严重,不能分离;③病变位于主动脉弓水平以上,位置过高,且X线表现呈缩窄型)住院治疗。血卟啉药物由江苏扬州生物制药厂生产,按每公斤体重5mg加5％葡萄糖稀释静脉滴
In our hospital since 1989, porphyrin plus preoperative radiotherapy for esophageal cancer has been performed and clinical observation data have been obtained. This article focuses on the pathological changes of hematoporphyrin plus radiotherapy for esophagectomy specimens. Materials and Methods: 10 cases of esophageal cancer patients were diagnosed as squamous cell carcinoma by pathological biopsy. The surgical examination revealed that the operation was difficult (1 lesion is longer, more than 6 cm, with external invasion; 2 lesions close to Aortic, trachea, heart and other important organs, estimated adhesion is severe, can not be separated; 3 lesions located above the level of the aortic arch, the position is too high, and X-ray showed a narrow type) hospitalization. Hematoporphyrins are manufactured by Jiangsu Yangzhou Biopharmaceutical Co., Ltd. and diluted by intravenous drip at 5 mg per kg body weight plus 5% glucose.